Page 6 - Scientific Library
Post-Translational Modifications (PTM) of Tubulin
In this post, I'd like to take a look at the current understanding of tubulin PTMs, that include tyrosination/detyrosination, Δ2-tubulin formation, acetylation, phosphorylation, ubiquitination, glutamylation,
New research tools targeting PCSK9 and LDLR
There is an increasing demand for new cholesterol-lowering therapies in addition to existing treatments (e.g. targeting statins). The pharmacological inhibition of PCSK9-mediated LDLR degradation
SiR fluorogenic probes: multicolour live-cell Imaging of Actin, Tubulin, DNA, and Lysosomes
Screen for inhibitors of PD-1 signalling with a complete cellular assay system
Immunotherapy represents a field in Drug Discovery which is quickly developing and leading to significant progress in treatments of a number of diseases, especially cancer. The approach is based on inducing,
How to activate or inhibit autophagy?
The term Autophagy was introduced by Christian de Duve during the Ciba Foundation Symposium on Lysosomes – which was held in London in February 1963. In 1974 he was honoured with the Nobel price in
3 functional assays to investigate actin dynamics
Today, I'd like to give you an overview about methods in actin research with validated R&DÂ products and kits which will allow you to measure binding to actin and effects on the polymerisation dynamics
New - Continued use immunotherapy cell line expressing recombinant PD-1
PD-1 / NFAT Reporter - Jurkat Cell Line
The PD-1 reporter cell line is
How to combine advantages of ELISAs and Arrays - Target validation with Quantibody®
On your journey to Biomarker profiling, you will reach the point where you need to quantify the proteins of interest identified along the way (eg. validation of semi-quantitative array results; biomarker
Stauprimide inhibits c-myc transcription in cancer cells
Stauprimide is known to prime Embryonic Stem Cells (ESC) by targeting the c-Myc-activating transcription factor NME2. Its mechanism of action is linked to the inhibition of the nuclear localization of
Cell-based assays with hPBMCs for cell therapy and drug discovery
Human Peripheral Blood Mononuclear Cells (hPBMCs) are essential for designing cellular models to be used in cell therapy and drug discovery research programs [1-7, 12]. Being able to access reliable and